SCHEMBL342459

SCHEMBL342459

CCCCC(CC)COCC(C)(C)C=O

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 6/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
ALDH1A1 P00352 7/20 0.44
TSHR P16473 5/20 0.44
TDP1 Q9NUW8 3/20 0.42
ATM Q13315 1/20 0.42
MMP9 P14780 1/20 0.40
MMP8 P22894 1/20 0.40
MMP14 P50281 1/20 0.40
CA2 P00918 3/20 0.38
RECQL P46063 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
LMNA P02545 2/20 0.35
MAPK1 P28482 1/20 0.34
HSD17B10 Q99714 1/20 0.34
NCOA1 Q15788 1/20 0.34
NCOA3 Q9Y6Q9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28027822 0.84 TSHR (0.45) CYP3A4L3MBTL1ALDH1A1TSHRTDP1
SCHEMBL12976468 0.80 CYP3A4 (0.55) CYP3A4L3MBTL1ALDH1A1TSHRTDP1
SCHEMBL12976464 0.80 CYP3A4 (0.55) CYP3A4L3MBTL1ALDH1A1TSHRTDP1
SCHEMBL20653184 0.80 CYP3A4 (0.55) CYP3A4L3MBTL1ALDH1A1TSHRTDP1
SCHEMBL30910034 0.80 CYP3A4 (0.55) CYP3A4L3MBTL1ALDH1A1TSHRTDP1
SCHEMBL9229713 0.79 CYP3A4 (0.50) CYP3A4L3MBTL1ALDH1A1TSHRTDP1
SCHEMBL10584689 0.78 CYP3A4 (0.56) CYP3A4L3MBTL1ALDH1A1TSHRTDP1
SCHEMBL13007639 0.77 CYP3A4 (0.51) CYP3A4L3MBTL1ALDH1A1TSHRTDP1
SCHEMBL18427246 0.77 CYP3A4 (0.51) CYP3A4L3MBTL1ALDH1A1TSHRTDP1
SCHEMBL18427203 0.76 CYP3A4 (0.50) CYP3A4L3MBTL1ALDH1A1TSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2651875-B1 AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS SIKA TECH AG (CH) 2017-08-30 EP claimed
CN-103261145-B There is the amine of secondary aliphatic amino group SIKA TECHNOLOGY AG (CH) 2016-04-13 CN claimed
US-9290603-B2 Amines having secondary aliphatic amino groups SIKA TECHNOLOGY AG (CH) 2016-03-22 US claimed
EP-2651875-A1 AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS Sika Technology AG (CH) 2013-10-23 EP claimed
US-20130237681-A1 AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS SIKA TECHNOLOGY AG (CH) 2013-09-12 US claimed
CN-103261145-A Amines having secondary aliphatic amino groups SIKA TECHNOLOGY AG 2013-08-21 CN claimed
WO-2012080264-A1 AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS SIKA TECHNOLOGY AG (CH) 2012-06-21 WO claimed
EP-2465842-A1 Amines with secondary aliphatic amines Sika Technology AG (CH) 2012-06-20 EP claimed
US-20100130674-A1 METHOD FOR THE PRODUCTION OF POLYURETHANE COMPOSITIONS WITH A LOW ISOCYANATE MONOMER CONTENT SIKA TECHNOLOGY AG (CH) 2010-05-27 US claimed
CN-101646704-A Method for the production of polyurethane compositions with a low isocyanate monomer content SIKA TECHNOLOGY AG CH 2010-02-10 CN claimed
EP-2132246-A1 METHOD FOR THE PRODUCTION OF POLYURETHANE COMPOSITIONS WITH A LOW ISOCYANATE MONOMER CONTENT Sika Technology AG (CH) 2009-12-16 EP claimed
WO-2008116927-A1 METHOD FOR THE PRODUCTION OF POLYURETHANE COMPOSITIONS WITH A LOW ISOCYANATE MONOMER CONTENT SIKA TECHNOLOGY AG (CH) 2008-10-02 WO claimed
EP-1975187-A1 Method for manufacturing polyurethane compounds with low isocyanate-monomer content Sika Technology AG (CH) 2008-10-01 EP claimed
US-12516147-B2 Aldimines and uses thereof BOSTIK SA (FR) 2026-01-06 US disclosed
US-12421345-B2 Polyimines and uses thereof BOSTIK SA (FR) 2025-09-23 US disclosed
EP-4077273-B1 ALDIMINES AND USES THEREOF BOSTIK SA (FR) 2025-04-02 EP disclosed
EP-0438696-A1 Process for the preparation of elastic compact or cellular moulded articles on the basis of elastomers containing N-substituted urea- and amide groups, such elastomers and polyoxyalkylene-polyamine mixtures, containing polyazomethines, suitable therefor BASF Aktiengesellschaft (DE) 1991-07-31 EP disclosed
US-4853454-A POLYETHER- OR -ESTERURETHANES AND POLYIMINECURING AGENTS; MOLDINGKMATERIALS; SOLVENT-FREE; SPRAYABLE PROTECTIVE COATINGS BASF AKTIENGESELLSCHAFT (DE) 1989-08-01 US disclosed
US-4789691-A REACTING POLYISOCYANATE, POLYAZOMETHINE, AND AROMATIC POLYAMINES BASF AKTIENGESELLSCHAFT (DE) 1988-12-06 US disclosed
EP-0254177-A2 Moisture-curable, storage-stable one-component polyurethane systems and their use BASF Aktiengesellschaft (DE) 1988-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237681-A1 AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS AAAS, PNMT, PARG CYP3A4 4204/4885L3MBTL1 2466/4885ALDH1A1 1074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.